In August 2026 FDA inspectors spent six days inside a Houston compounding pharmacy and documented 14 problems with how it made sterile injectables, including compounded GLP-1 shots; its tirzepatide vials were later recalled. The pharmacy was state-licensed. A license is where vetting starts, not where it ends. Here is the rest.
By Dr. SkinnyVIP · Published October 20, 2026
“Houston Rx LLC, Houston, TX - 503A Facility - 483 Issued 08/28/2026”
Medical Daily reported that the inspection documented 14 observations, including exposed skin in sterile areas and research-grade ingredients, and that the pharmacy's compounded tirzepatide vials were recalled over sterility concerns. A Form 483 lists what inspectors observed; it is not a final FDA finding of violation. But it is public, and it is exactly the kind of record a patient can check in five minutes before injecting a product.
FDA's own guidance to patients is short: obtain a prescription from your doctor and fill it at a state-licensed pharmacy. The checklist below is how to confirm that is actually what happened.
1. Is the pharmacy licensed in its home state, and in yours? Look the pharmacy up on its home state Board of Pharmacy site. Then check your own state's board: a pharmacy shipping across state lines generally needs a nonresident pharmacy license in the receiving state, and some states (California, for example) also require a separate sterile-compounding license. The name on the license must match the name on your vial.
2. 503A or 503B? A 503A pharmacy compounds for an individual patient from a prescription and is regulated primarily by its state board. A 503B outsourcing facility registers with FDA, follows manufacturing-grade rules and can produce in bulk. Either can be legitimate; what matters is that the pharmacy is honest about which it is and that the paperwork matches. FDA publishes the registered 503B list.
3. Where did the active ingredient come from? This is the question most patients never ask and the one the Houston inspection turned on. Ask the pharmacy for the name of its tirzepatide API supplier and whether that supplier is FDA-registered. Since September 2025, FDA has run a "green list" import alert, Import Alert 66-80, that detains GLP-1 active ingredients at the border unless the source facility has been evaluated; per the National Law Review's summary, "APIs from these 'green-listed' facilities are exempt from detention... All other GLP-1 APIs from unverified foreign sources may be subject to automatic detention." The words "research grade" anywhere in the answer end the conversation.
4. Can they produce a certificate of analysis for your lot? A real COA names the testing lab, the lot number (which should match your vial), the test date, and results for identity, potency (assay against the labeled strength), sterility, bacterial endotoxin and pH. A generic PDF on a website with no lot number is marketing, not a COA. A pharmacy that tests every lot will not mind being asked.
5. What is the inspection and recall history? Search the pharmacy's name on FDA's compounding inspections and recalls page and on its state board's disciplinary-actions page. One old observation that was corrected is normal; a recall for sterility is not.
6. Does the label look like a prescription label? Your name, the prescriber's name, the pharmacy's name and address, the drug and strength, the lot or prescription number, a beyond-use date, and storage instructions. "For research use only," "not for human consumption," or no patient name at all means it was never dispensed to you as a prescription.
7. Was there a real prescription chain? A licensed clinician reviewed your health history and wrote a prescription; the pharmacy dispensed against it. If a seller offers the product without that step, or tells you the clinician review is a formality, FDA's telehealth red flags apply: claims that the compounded drug is the same as an FDA-approved drug, prices that seem too good to be true, and medicine that looks different from what you were told to expect.
1. "What is your pharmacy license number in [my state], and your home state?"
2. "Are you a 503A pharmacy or a 503B outsourcing facility?"
3. "Who supplies your tirzepatide active ingredient, and is that facility on FDA's Import Alert 66-80 green list?"
4. "Can you send the certificate of analysis for the lot you dispensed to me?"
5. "Have you had any FDA Form 483 observations or recalls in the last three years?"
If the answers come back quickly and specifically, you have a pharmacy. If they come back vague, you have a decision to make.
How SkinnyVIP handles this. Every prescription comes from a licensed clinician who has reviewed your health history; prescription is not guaranteed. We work only with state-licensed 503A compounding pharmacies, and your medication arrives labeled with the dispensing pharmacy's name and license information as the law requires, so you can verify it yourself. You can ask us which pharmacy filled your prescription and for the lot documentation that pharmacy provides. Compounded medications are not FDA-approved products. $695 for a 3-month plan (about $232 a month) or $350 for one month, the same at every dose, no membership, nothing renews.
Search the pharmacy's name on its home state Board of Pharmacy website, then on your own state's board, since pharmacies shipping into your state generally need a nonresident license there. The name on the license must match the name on your prescription label.
The testing lab's name, the lot number matching your vial, the test date, and results for identity, potency against the labeled strength, sterility, bacterial endotoxin and pH. A document without a lot number is not a COA for your medication.
A 'green list' import alert FDA established in September 2025 for GLP-1 active pharmaceutical ingredients. Ingredients from facilities FDA has evaluated are exempt from detention at the border; GLP-1 APIs from unverified foreign sources may be detained. Ask your pharmacy whether its supplier is on the list.
We work only with state-licensed 503A compounding pharmacies, and your medication arrives labeled with the dispensing pharmacy's name and license information. Patients can ask us which pharmacy filled their prescription and for the lot documentation that pharmacy provides. Compounded medications are not FDA-approved products.
$695 for a 3-month plan (about $232/month) or $350 for one month, any dose. You only pay if a licensed clinician approves treatment.
Start your consultationCompounded tirzepatide is prepared by licensed compounding pharmacies under physician supervision. Compounded medications are not FDA-approved products, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Compounded tirzepatide is separate from FDA-approved Mounjaro® and Zepbound®. A licensed clinician reviews every request; prescription is not guaranteed. Individual results vary. Not affiliated with Novo Nordisk (Ozempic®/Wegovy®) or Eli Lilly (Mounjaro®/Zepbound®). This page is general information about published coverage policies, not insurance, legal or medical advice; confirm details with your plan.